Kutatási jelek – Signal Engine
- A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions — Renal cell carcinoma
- Clinical utility and future perspectives of liquid biopsy in colorectal cancer — Colorectal cancer
- ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial — Ovarian cancer
- The global burden of stomach cancer and its risk factors from 1990 to 2021: findings from the Global Burden of Disease Study 2021 — Gastric cancer
- ... — Colorectal cancer
- Exploring the efficacy of fluorouracil and platinum based chemotherapy in advanced hepatocellular carcinoma to bridge the treatment gap in resource limited settings — Hepatocellular carcinoma
- Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial — Hepatocellular carcinoma
- Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies — Melanoma
- Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies — Gastric cancer
- Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives — Gastric cancer
- Improved overall survival in an anti‑PD‑L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial — Glioblastoma
- NSCLC: Current Evidence on Its Pathogenesis, Integrated Treatment, and Future Perspectives — NSCLC
- Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial — Hepatocellular carcinoma
- Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models — Hepatocellular carcinoma
- Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson — NSCLC
- Bevacizumab-FOLFOXIRI in First Line Treatment of BRAF V600E - Mutant Metastatic Colorectal Cancer: A Single-Center Study — Colorectal cancer
- Harnessing gut microbiota for colorectal cancer therapy: from clinical insights to therapeutic innovations — Colorectal cancer
- Hepatocellular carcinoma stem cells: the current state of small molecule-based inhibitors — Hepatocellular carcinoma
- Real‑World Outcomes of Atezolizumab‑Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort — Hepatocellular carcinoma
- Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer — Prostate cancer